Show simple item record

Combining the antigen-presenting cell activator eftilagimod alpha (Soluble Lag-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of Tacti-002 (Phase Ii)

dc.contributor.authorIams, W.
dc.contributor.authorFelip, E.
dc.contributor.authorMajem, M.
dc.contributor.authorDoger, B.
dc.contributor.authorClay, T.
dc.contributor.authorCarcereny, E.
dc.contributor.authorBondarenko, I.
dc.contributor.authorPeguero, J.
dc.contributor.authorCobo-Dols, M.
dc.contributor.authorForster, M.
dc.contributor.authorUrsol, G.
dc.contributor.authorKalinka, E.
dc.contributor.authorLedo, G. G.
dc.contributor.authorMartinez, L. V.
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorBalea, B. C.
dc.contributor.authorKefas, J.
dc.contributor.authorMueller, C.
dc.contributor.authorBrignone, C.
dc.contributor.authorTriebel, F.
dc.date.accessioned2023-05-17T09:50:56Z
dc.date.available2023-05-17T09:50:56Z
dc.date.issued2022en
dc.identifier.citationIams W, Felip E, Majem M, Doger B, Clay T, Carcereny E, et al. Combining the Antigen-Presenting Cell Activator Eftilagimod Alpha (Soluble Lag-3) and Pembrolizumab: Efficacy Results from the 1st Line Non-Small Cell Lung Cancer Cohort of Tacti-002 (Phase Ii). Journal for immunotherapy of cancer. 2022 Nov;10:A1529-A. PubMed PMID: WOS:000919423401574.en
dc.identifier.doi10.1136/jitc-2022-SITC2022.1470en
dc.identifier.urihttp://hdl.handle.net/10541/626282
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1136/jitc-2022-SITC2022.1470en
dc.titleCombining the antigen-presenting cell activator eftilagimod alpha (Soluble Lag-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of Tacti-002 (Phase Ii)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentVanderbilt Ingram Cancer Center, Nashville, TN,en
dc.identifier.journalJournal for Immunotherapy of Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record